Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
why发布了新的文献求助10
1秒前
CipherSage的应助被牛八先生采纳,获得10
2秒前
3秒前
NexusExplorer的应助被鱼鱼鱼采纳,获得10
3秒前
云起天山发布了新的文献求助10
3秒前
3秒前
钰c完成签到,获得积分20
3秒前
littleblack发布了新的文献求助10
4秒前
兴奋的高跟鞋完成签到,获得积分10
4秒前
何晨完成签到,获得积分10
5秒前
钰c发布了新的文献求助10
5秒前
深情安青的应助被www采纳,获得10
6秒前
小菠萝完成签到 ,获得积分10
6秒前
KX发布了新的文献求助30
7秒前
7秒前
Owen的应助被Ly采纳,获得10
7秒前
紧张的宛凝完成签到 ,获得积分10
7秒前
7秒前
科研通AI6.4的应助被大气世平采纳,获得10
8秒前
8秒前
wanghh发布了新的文献求助10
8秒前
fengzhigean发布了新的文献求助10
8秒前
9秒前
9秒前
完美世界的应助被震动的牛排采纳,获得10
9秒前
无花果的应助被梨花酒采纳,获得10
9秒前
10秒前
希望天下0贩的0的应助被why采纳,获得10
11秒前
辛夷发布了新的文献求助10
11秒前
一半发布了新的文献求助10
12秒前
MAJIALE发布了新的文献求助10
12秒前
醉熏的文轩完成签到,获得积分10
13秒前
顾以白发布了新的文献求助10
13秒前
13秒前
13秒前
14秒前
qr发布了新的文献求助10
14秒前
无花果的应助被初景采纳,获得100
14秒前
sakatagintoki发布了新的文献求助10
14秒前
shine发布了新的文献求助30
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 888
Rosenblum, Global Change Biology 800
Holistic Discourse Analysis, Second Edition by Robert E. Longacre (2012-09-10) 666
Final Report for the 2-D Test of Model 901 Rotor and Wing Airfoils (BSWT 592) 528
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 520
Organizational Behavior 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 物理 有机化学 化学工程 内科学 生物化学 复合材料 催化作用 心理学 细胞生物学 无机化学 电极 光电子学 人工智能
热门帖子
关注 科研通微信公众号,转发送积分 7885636
求助须知:如何正确求助?哪些是违规求助? 9398154
关于积分的说明 20825204
捐赠科研通 7487845
什么是DOI,文献DOI怎么找? 3356255
关于科研通互助平台的介绍 2495066
邀请新用户注册赠送积分活动 2384111